Justin Holland has over 20 years of experience in pharmaceutical testing to support all phases of drug product development from pre-clinical through to commercial release. He joined the company in 2009 and oversees the analytical development and quality control teams at the Nottingham site primarily supporting the development of early phase drug products for Phase I clinical trials. 

His expertise includes working with poorly soluble molecules, modified release formulations and paediatric drug products and the associated testing.  

Justin holds a MChem degree in Chemistry from the Nottingham Trent University.

Kingsley has over 20 years’ experience in product development within the pharmaceutical and consumer healthcare industries, including experience in developing palatable formulations.

Prior to joining Quotient Sciences, he worked in a contract formulation development organisation that was acquired by Quotient in 2015.  In his current role, Kingsley leads the formulation development team in Nottingham and provides technical oversight of paediatric development projects, ensuring programmes are appropriately resourced and delivered to key development milestones.

Professor Hannah Batchelor specialises in developing medicines tailored to the needs of children, with a particular focus on ageappropriate formulations, biorelevant dissolution testing, and the application of cyberphysical systems to transform drug product development. Drawing on experience across academia, the NHS, and the pharmaceutical industry, her work bridges fundamental science with realworld patient needs.

She is currently Professor at the Strathclyde Institute of Pharmacy and Biomedical Sciences, where she leads research on improving the design, manufacture, and performance prediction of paediatric medicines. 

Her contributions influence regulatory guidance, industrial practice, and global initiatives to enhance medicine acceptability and effectiveness for children. 

Jenny Walsh has over 30 years’ experience in the Pharmaceutical and Consumer Healthcare Industry and has been an independent consultant specialising in the development of age-appropriate medicines for children since 2011. She has actively contributed to numerous global paediatric developments projects, including Paediatric Investigation Plans (PIPs) and Pediatric Study Plans (PSPs) as well as providing support to the World Health Organization (WHO).  

She is a founder member of and subject matter expert for the European Paediatric Formulation Initiative (EuPFI) where her main interests include paediatric administration devices (workstream lead), taste masking and taste/palatability assessment, age-appropriate formulations and patient acceptability, and excipients. She is also an advisor to “conect4children Stichting” (c4c-S) pan-European network and the Society for Paediatric Medicines & Healthcare Initiative (India).  

Jenny is a UK registered pharmacist with her Bachelor of Pharmacy awarded by the University of Wales Institute of Science and Technology Cardiff and her PhD in pharmaceutical drug delivery from the University of Nottingham.

Catherine Tuleu, research, inherently translational, ranges from formulation, methodology development to clinical implementation, integrating the following themes: children centric excipient research; repurposing by reformulating for better medicines for children; development of innovative age-appropriate dosage forms (especially for under 5s); administration issues and devices and sensory pharmaceuticsTM (dosage form acceptability and in vitro/in vivo taste assessment). 

Her spin out company senCeuTics Ltd. specializes in pharmaceutical sensory evaluation and offers a full spectrum of preclinical, clinical and paediatric formulation services under one roof. 

She is the founder and chairperson of the European Paediatric Formulation Initiative (EuPFI), a consortium working in a pre-competitive way on paediatric drug formulations.